1.15 – Structural Chemogenomics Databases to Navigate Protein–Ligand Interaction Space
暂无分享,去创建一个
Albert J. Kooistra | Georgi K. Kanev | I.J.P. de Esch | C. de Graaf | A. Kooistra | I. D. Esch | C. Graaf
[1] R. Rodenburg,et al. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. , 2015, Cell metabolism.
[2] Manuela Pavan,et al. DRAGON SOFTWARE: AN EASY APPROACH TO MOLECULAR DESCRIPTOR CALCULATIONS , 2006 .
[3] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[4] Katrin Stierand,et al. Drawing the PDB: Protein-Ligand Complexes in Two Dimensions. , 2010, ACS medicinal chemistry letters.
[5] F. Sanger,et al. Nucleotide sequence of bacteriophage φX174 DNA , 1977, Nature.
[6] Venkatesh,et al. Bioinformatics, pharma and farmers. , 1999, Trends in biotechnology.
[7] Robert D. Finn,et al. New developments in the InterPro database , 2007, Nucleic Acids Res..
[8] Yang Zhang,et al. BioLiP: a semi-manually curated database for biologically relevant ligand–protein interactions , 2012, Nucleic Acids Res..
[9] Fei Long,et al. The PDB_REDO server for macromolecular structure model optimization , 2014, IUCrJ.
[10] J. Mestres,et al. Drug‐Target Networks , 2010, Molecular informatics.
[11] Friedrich Rippmann,et al. Pocketome of Human Kinases: Prioritizing the ATP Binding Sites of (Yet) Untapped Protein Kinases for Drug Discovery , 2015, J. Chem. Inf. Model..
[12] Andreas Bender,et al. Modelling ligand selectivity of serine proteases using integrative proteochemometric approaches improves model performance and allows the multi-target dependent interpretation of features. , 2014, Integrative biology : quantitative biosciences from nano to macro.
[13] Andreas Bender,et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.
[14] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.
[15] E. Kellenberger,et al. A simple and fuzzy method to align and compare druggable ligand‐binding sites , 2008, Proteins.
[16] Shaoyong Lu,et al. ASBench: benchmarking sets for allosteric discovery , 2015, Bioinform..
[17] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[18] Yu Luo,et al. Allosite: a method for predicting allosteric sites , 2013, Bioinform..
[19] María Martín,et al. UniProt: A hub for protein information , 2015 .
[20] Bas Vroling,et al. GPCRdb: an information system for G protein-coupled receptors , 2015, Nucleic Acids Res..
[21] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[22] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[23] T. Klabunde. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands , 2007, British journal of pharmacology.
[24] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[25] Stefan Verhoeven,et al. 3D-e-Chem GPCRdb KNIME nodes: v1.0.6 , 2016 .
[26] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[27] N. O. Manning,et al. The protein data bank , 1999, Genetica.
[28] Gerard J. P. van Westen,et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .
[29] Didier Rognan,et al. sc-PDB: a 3D-database of ligandable binding sites—10 years on , 2014, Nucleic Acids Res..
[30] Peter Ertl,et al. Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization , 2010, Molecular informatics.
[31] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[32] Kenji Mizuguchi,et al. PoSSuM v.2.0: data update and a new function for investigating ligand analogs and target proteins of small-molecule drugs , 2014, Nucleic Acids Res..
[33] P. Argos,et al. Knowledge‐based protein secondary structure assignment , 1995, Proteins.
[34] Tatiana A. Tatusova,et al. NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy , 2011, Nucleic Acids Res..
[35] Gerard J. Kleywegt,et al. Crystallographic refinement of ligand complexes , 2006, Acta crystallographica. Section D, Biological crystallography.
[36] E. Knapp,et al. Database of protein complexes with multivalent binding ability: Bival‐bind , 2014, Proteins.
[37] I. D. de Esch,et al. KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. , 2014, Journal of medicinal chemistry.
[38] D. Schrag,et al. Oxygen Isotope Constraints on the Sulfur Cycle over the Past 10 Million Years , 2004, Science.
[39] J. Baell,et al. Chemistry: Chemical con artists foil drug discovery , 2014, Nature.
[40] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[41] P. Radivojac,et al. Analysis of protein function and its prediction from amino acid sequence , 2011, Proteins.
[42] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[43] S. Lampel,et al. The druggable genome: an update. , 2005, Drug discovery today.
[44] Robert D. Finn,et al. iPfam: a database of protein family and domain interactions found in the Protein Data Bank , 2013, Nucleic Acids Res..
[45] Hans-Werner Mewes,et al. The PIR-International Protein Sequence Database , 1992, Nucleic Acids Res..
[46] C. Ehrt,et al. Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design. , 2016, Journal of medicinal chemistry.
[47] J. Drews. Stategic trends in the drug industry. , 2003, Drug discovery today.
[48] Douglas E. V. Pires,et al. Platinum: a database of experimentally measured effects of mutations on structurally defined protein–ligand complexes , 2014, Nucleic Acids Res..
[49] Ying Xu,et al. Protein domain decomposition using a graph-theoretic approach , 2000, Bioinform..
[50] Joanna L. Sharman,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..
[51] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[52] Steven E. Brenner,et al. SCOPe: Structural Classification of Proteins—extended, integrating SCOP and ASTRAL data and classification of new structures , 2013, Nucleic Acids Res..
[53] J. Dearden,et al. QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.
[54] Roman A. Laskowski,et al. LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..
[55] Philippe Roche,et al. 2P2IHUNTER: a tool for filtering orthosteric protein–protein interaction modulators via a dedicated support vector machine , 2014, Journal of The Royal Society Interface.
[56] E. Myers,et al. Basic local alignment search tool. , 1990, Journal of molecular biology.
[57] Chris de Graaf,et al. Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure. , 2013, Journal of medicinal chemistry.
[58] J. Bonfield,et al. Finishing the euchromatic sequence of the human genome , 2004, Nature.
[59] Jürgen Bajorath,et al. A Perspective on Computational Chemogenomics , 2013, Molecular informatics.
[60] Alexander Tropsha,et al. Curation of chemogenomics data. , 2015, Nature chemical biology.
[61] J. D. Elliott,et al. Drug discovery in the next millennium. , 2000, Annual review of pharmacology and toxicology.
[62] Qi Wang,et al. Toward understanding the molecular basis for chemical allosteric modulator design. , 2012, Journal of Molecular Graphics and Modelling.
[63] Olivier Sperandio,et al. One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. , 2013, Drug discovery today.
[64] Antony J. Williams,et al. Bigger data, collaborative tools and the future of predictive drug discovery , 2014, Journal of Computer-Aided Molecular Design.
[65] Haruki Nakamura,et al. The Protein Data Bank archive as an open data resource , 2014, Journal of Computer-Aided Molecular Design.
[66] Didier Rognan,et al. Binding of Protein Kinase Inhibitors to Synapsin I Inferred from Pair-Wise Binding Site Similarity Measurements , 2010, PloS one.
[67] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[68] Robert D. Finn,et al. The Pfam protein families database: towards a more sustainable future , 2015, Nucleic Acids Res..
[69] E. Jacoby,et al. Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.
[70] Maria Jesus Martin,et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..
[71] Tudor I. Oprea,et al. Systems chemical biology. , 2007 .
[72] Sébastien Moretti,et al. Bgee: Integrating and Comparing Heterogeneous Transcriptome Data Among Species , 2008, DILS.
[73] George Papadatos,et al. MyChEMBL: A Virtual Platform for Distributing Cheminformatics Tools and Open Data , 2014, Challenges.
[74] Joanna Owens,et al. Target validation: Determining druggability , 2007, Nature Reviews Drug Discovery.
[75] W. L. Jorgensen. The Many Roles of Computation in Drug Discovery , 2004, Science.
[76] Christian Kramer,et al. Quality Issues with Public Domain Chemogenomics Data , 2013, Molecular informatics.
[77] Bryan L. Roth,et al. Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.
[78] T. Geppert,et al. Biological Networks and Drug Discovery—Where Do We Stand? , 2014, Drug development research.
[79] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[80] Ion I. Mandoiu,et al. In Silico Enzymatic Synthesis of a 400 000 Compound Biochemical Database for Nontargeted Metabolomics , 2013, J. Chem. Inf. Model..
[81] Gary D. Bader,et al. Pathguide: a Pathway Resource List , 2005, Nucleic Acids Res..
[82] J. Bajorath,et al. How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment , 2012, The AAPS Journal.
[83] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[84] P Kolb,et al. GPCRdb: the G protein‐coupled receptor database – an introduction , 2016, British journal of pharmacology.
[85] Rafael C. Jimenez,et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..
[86] Didier Rognan,et al. Computational Profiling of Bioactive Compounds Using a Target-Dependent Composite Workflow , 2013, J. Chem. Inf. Model..
[87] J. Bajorath. Computational analysis of ligand relationships within target families. , 2008, Current opinion in chemical biology.
[88] Haruki Nakamura,et al. The Protein Data Bank at 40: reflecting on the past to prepare for the future. , 2012, Structure.
[89] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[90] Akira R. Kinjo,et al. Protein Data Bank Japan (PDBj): maintaining a structural data archive and resource description framework format , 2011, Nucleic Acids Res..
[91] Tom L. Blundell,et al. CREDO: a structural interactomics database for drug discovery , 2013, Database J. Biol. Databases Curation.
[92] Rafael C. Jimenez,et al. The IntAct molecular interaction database in 2012 , 2011, Nucleic Acids Res..
[93] Marco Biasini,et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information , 2014, Nucleic Acids Res..
[94] Didier Rognan,et al. Proteome-scale docking: myth and reality. , 2013, Drug discovery today. Technologies.
[95] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[96] Aurélien Grosdidier,et al. SwissTargetPrediction: a web server for target prediction of bioactive small molecules , 2014, Nucleic Acids Res..
[97] P. Clemons,et al. Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.
[98] Jürgen Bajorath,et al. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. , 2014, Journal of medicinal chemistry.
[99] Rolf Apweiler,et al. The SWISS-PROT protein sequence data bank and its new supplement TREMBL , 1996, Nucleic Acids Res..
[100] María Martín,et al. Activities at the Universal Protein Resource (UniProt) , 2013, Nucleic Acids Res..
[101] Andrew R Thomson,et al. De novo protein design: how do we expand into the universe of possible protein structures? , 2015, Current opinion in structural biology.
[102] Damian Szklarczyk,et al. STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data , 2015, Nucleic Acids Res..
[103] J. Sussman,et al. JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia , 2013 .
[104] M. Rask-Andersen,et al. Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.
[105] Nuno A. Fonseca,et al. Expression Atlas update—an integrated database of gene and protein expression in humans, animals and plants , 2015, Nucleic Acids Res..
[106] Ruedi Stoop,et al. An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..
[107] Saskia Nijmeijer,et al. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. , 2011, Journal of medicinal chemistry.
[108] Jessica Morrison,et al. POLICY Ethanol and petroleum industries pan new Renewable Fuel Standard , 2016 .
[109] G. Schuler. Pieces of the puzzle: expressed sequence tags and the catalog of human genes , 1997, Journal of Molecular Medicine.
[110] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[111] J. Smeitink,et al. Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying ibipinabant-induced myotoxicity , 2015, Scientific Reports.
[112] Scott Federhen,et al. The NCBI Taxonomy database , 2011, Nucleic Acids Res..
[113] Philippe Roche,et al. 2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein–protein interactions , 2016, Database J. Biol. Databases Curation.
[114] Richard D. Smith,et al. Recent improvements to Binding MOAD: a resource for protein–ligand binding affinities and structures , 2014, Nucleic Acids Res..
[115] David S. Goodsell,et al. The RCSB Protein Data Bank: views of structural biology for basic and applied research and education , 2014, Nucleic Acids Res..
[116] Anna Vulpetti,et al. Chemogenomics in drug discovery: computational methods based on the comparison of binding sites. , 2012, Future medicinal chemistry.
[117] Jaap Heringa,et al. Electron Density Fingerprints (EDprints): Virtual Screening Using Assembled Information of Electron Density , 2010, J. Chem. Inf. Model..
[118] John D. Westbrook,et al. The Structural Biology Knowledgebase: a portal to protein structures, sequences, functions, and methods , 2011, Journal of Structural and Functional Genomics.
[119] M. M. Sanders,et al. From the protein's perspective: the benefits and challenges of protein structure-based pharmacophore modeling , 2012 .
[120] J. V. Moran,et al. Initial sequencing and analysis of the human genome. , 2001, Nature.
[121] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[122] J. Bajorath,et al. What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data , 2013, The AAPS Journal.
[123] Adam Godzik,et al. Flexible structure alignment by chaining aligned fragment pairs allowing twists , 2003, ECCB.
[124] Dusanka Janezic,et al. ProBiS-CHARMMing: Web Interface for Prediction and Optimization of Ligands in Protein Binding Sites , 2015, J. Chem. Inf. Model..
[125] H. Berman. The Protein Data Bank: a historical perspective. , 2008, Acta crystallographica. Section A, Foundations of crystallography.
[126] Shuai Li,et al. ASD v2.0: updated content and novel features focusing on allosteric regulation , 2013, Nucleic Acids Res..
[127] Chris de Graaf,et al. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study , 2015, J. Chem. Inf. Model..
[128] M. Murcko,et al. Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.
[129] Barend Mons,et al. Open PHACTS: semantic interoperability for drug discovery. , 2012, Drug discovery today.
[130] Ilya N. Shindyalov,et al. PDP: protein domain parser , 2003, Bioinform..
[131] Ben M. Webb,et al. ModBase, a database of annotated comparative protein structure models and associated resources , 2013, Nucleic Acids Res..
[132] Lisa Jarvis,et al. The year in new drugs , 2018 .
[133] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[134] Takeshi Kawabata,et al. Detection of pockets on protein surfaces using small and large probe spheres to find putative ligand binding sites , 2007, Proteins.
[135] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[136] Timothy B. Stockwell,et al. The Sequence of the Human Genome , 2001, Science.
[137] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[138] Mathias Wawer,et al. Similarity-Potency Trees: A Method to Search for SAR Information in Compound Data Sets and Derive SAR Rules , 2010, J. Chem. Inf. Model..
[139] Tudor I. Oprea,et al. WOMBAT: World of Molecular Bioactivity , 2005 .
[140] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[141] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[142] Adel Golovin,et al. MSDsite: A database search and retrieval system for the analysis and viewing of bound ligands and active sites , 2004, Proteins.
[143] Sartaj Sahni,et al. Multicore and GPU algorithms for Nussinov RNA folding , 2014, BMC Bioinformatics.
[144] Tina Ritschel,et al. Pharmacophore Fingerprint-Based Approach to Binding Site Subpocket Similarity and Its Application to Bioisostere Replacement , 2012, J. Chem. Inf. Model..
[145] Nagasuma R. Chandra,et al. PLIC: protein–ligand interaction clusters , 2014, Database J. Biol. Databases Curation.
[146] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[147] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[148] Shuai Li,et al. Alloscore: a method for predicting allosteric ligand-protein interactions , 2016, Bioinform..
[149] Michael K. Gilson,et al. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology , 2015, Nucleic Acids Res..
[150] Eric T. Kim,et al. How does a drug molecule find its target binding site? , 2011, Journal of the American Chemical Society.
[151] Jaewoo Kang,et al. K-Map: connecting kinases with therapeutics for drug repurposing and development , 2013, Human Genomics.
[152] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[153] Chris de Graaf,et al. KLIFS: a structural kinase-ligand interaction database , 2015, Nucleic Acids Res..
[154] Didier Rognan,et al. sc-PDB-Frag: A Database of Protein-Ligand Interaction Patterns for Bioisosteric Replacements , 2014, J. Chem. Inf. Model..
[155] Ross McGuire,et al. Data-driven medicinal chemistry in the era of big data. , 2014, Drug discovery today.
[156] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[157] Abhik Mukhopadhyay,et al. PDBe: improved accessibility of macromolecular structure data from PDB and EMDB , 2015, Nucleic Acids Res..
[158] Tom L. Blundell,et al. TIMBAL v2: update of a database holding small molecules modulating protein–protein interactions , 2013, Database J. Biol. Databases Curation.
[159] Gisbert Schneider,et al. De novo design - hop(p)ing against hope. , 2013, Drug discovery today. Technologies.
[160] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[161] Juergen Haas,et al. The Protein Model Portal—a comprehensive resource for protein structure and model information , 2013, Database J. Biol. Databases Curation.
[162] Kwong-Sak Leung,et al. iview: an interactive WebGL visualizer for protein-ligand complex , 2014, BMC Bioinformatics.
[163] Andreas Prlic,et al. Pre-calculated protein structure alignments at the RCSB PDB website , 2010, Bioinform..
[164] Huaiyu Mi,et al. The InterPro protein families database: the classification resource after 15 years , 2014, Nucleic Acids Res..
[165] R. Leurs,et al. A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design , 2013, British journal of pharmacology.
[166] Didier Rognan,et al. Encoding Protein-Ligand Interaction Patterns in Fingerprints and Graphs , 2013, J. Chem. Inf. Model..
[167] Philip E. Bourne,et al. SuperTarget goes quantitative: update on drug–target interactions , 2011, Nucleic Acids Res..
[168] W. Kabsch,et al. Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.
[169] David A. Lee,et al. CATH: comprehensive structural and functional annotations for genome sequences , 2014, Nucleic Acids Res..
[170] Maria Jesus Martin,et al. SIFTS: Structure Integration with Function, Taxonomy and Sequences resource , 2012, Nucleic Acids Res..
[171] Isidro Cortes-Ciriano,et al. Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects , 2015 .
[172] Radka Svobodová Vareková,et al. ValidatorDB: database of up-to-date validation results for ligands and non-standard residues from the Protein Data Bank , 2014, Nucleic Acids Res..
[173] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[174] Satoshi Niijima,et al. GLIDA: GPCR—ligand database for chemical genomics drug discovery—database and tools update , 2007, Nucleic Acids Res..
[175] Georgi K. Kanev,et al. PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design. , 2016, Journal of medicinal chemistry.
[176] Jie Li,et al. PDB-wide collection of binding data: current status of the PDBbind database , 2015, Bioinform..
[177] Haruki Nakamura,et al. Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.
[178] Minoru Kanehisa,et al. KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..
[179] Yang Zhang,et al. GLASS: a comprehensive database for experimentally validated GPCR-ligand associations , 2015, Bioinform..
[180] Themis Lazaridis,et al. Water at biomolecular binding interfaces. , 2007, Physical chemistry chemical physics : PCCP.
[181] Kai-Cheng Hsu,et al. KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms , 2012, Nucleic Acids Res..
[182] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[183] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[184] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[185] Benjamin A. Shoemaker,et al. IBIS (Inferred Biomolecular Interaction Server) reports, predicts and integrates multiple types of conserved interactions for proteins , 2011, Nucleic Acids Res..
[186] J. Mestres,et al. On the origins of drug polypharmacology , 2013 .